Hormonal
Adopting low glycaemic index (GI) or low glycaemic load (GL) dietary patterns results in small but clinically significant improvements in glycaemic control (HbA1c) and cardiometabolic risk factors (lipids, inflammation, adiposity) for adults with moderately controlled type 1 and type 2 diabetes, even when concurrent with standard pharmacotherapy.
If you have type 1 or type 2 diabetes, switching to a low GI or GL diet can help lower your HbA1c and improve cholesterol and inflammation, even if you are already taking diabetes medication. You don't need to change everything at once; focus on replacing high-GI carbohydrates (like white bread and sugary drinks) with lower-GI options (like legumes and whole grains). This approach is safe, effective, and works alongside your current treatment plan to help you reach your health goals.
This synthesis suggests that low GI/GL dietary patterns result in small important improvements in established targets of glycaemic control, blood lipids, adiposity, and inflammation beyond concurrent treatment with hyperglycaemia drugs or insulin, predominantly in adults with moderately controlled type 1 and type 2 diabetes.
Why this rating
High certainty for HbA1c and moderate for secondary outcomes, based on GRADE assessment of RCTs.
Source
Effect of low glycaemic index or load dietary patterns on glycaemic control and cardiometabolic risk factors in diabetes: systematic review and meta-analysis of randomised controlled trials
Laura Chiavaroli et al. · BMJ · 2021
DOI 10.1136/bmj.n1651
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →